$INSM

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

Insmed Inc. (INSM) added former Sanofi CEO Paul Hudson and Verily Health CFO Utpal Koppikar to its board, enhancing commercial and financial expertise. The company is expanding globally and advancing its drug pipeline. Hudson and Koppikar bring extensive experience in pharmaceutical operations and financial management, respectively.

INSMED Inc (INSM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Insmed Appoints Two New Directors to Its Board —Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J., Oct. 20, 2026 -- Insme

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.

Insmed Inc. (INSM) will present new data on its respiratory portfolio at CHEST 2026 and IDWeek 2026. Key studies include TPIP for PAH and PH-ILD, BRINSUPRI for bronchiectasis, and ARIKAYCE for MAC lung disease. The company aims to showcase the strength and diversity of its respiratory treatments.

BMO Capital analysts maintained Buy ratings on Pfizer (PFE), ACADIA Pharmaceuticals (ACAD), and Insmed (INSM), with price targets of $35.00, $34.00, and $192.00 respectively. Current share prices are $28.40, $19.56, and $99.39. Analyst consensus for these stocks is Moderate Buy for PFE and ACAD, and Strong Buy for INSM, with average price targets of $29.62, $33.29, and $197.84 respectively.

Truist Securities previewed Q3 2026 earnings for eight biotech companies, highlighting Insmed (INSM), BridgeBio (BBIO), and Neurocrine (NBIX) for potential volatility. Insmed's Brinsupri forecast was reduced due to lower prescription trends. BridgeBio's revenue surged 202% to $713M with 94% gross margins. The FDA accepted BridgeBio's NDA for infigratinib, with analysts maintaining Buy ratings and price targets.

BofA Securities reduced its price target for Insmed (INSM) to $207 from $214, citing valuation concerns, while maintaining a Buy rating. The company reported strong performance for Brinsupri, with revenue growth of 186% over the last twelve months and raised fiscal 2026 guidance to $1.25B-$1.4B. Insmed shares have fallen 42% year-to-date, with a market cap of $21.97B. Analysts anticipate sales growth and potential market expansion.

UBS maintained a Buy rating on Insmed (INSM) with a $172 price target, despite lowering Brinsupri sales estimates for 2H 2026. The stock is down 41.5% YTD. UBS cites compelling valuation and peak sales potential over $5B. Other analysts also show positive sentiment, with recent regulatory approvals in Japan and a U.S. FDA priority review for Arikayce.